Signalife Sees Accretive Purchase and Financial Commitments
Dr. Harmison, the Company's President and CEO, stated: "I anticipateclosing these transactions in the upcoming two to four weeks, which comprisesignificant business for the Company. With the experiential base developedduring my tenure regarding the ECG data generated from the usage of ourtechnologies -- not only by health care providers but also through numerousAthletes for Life-sponsored mobile health care screenings -- there are nownumerous additional revenue streams that have naturally become available tothe Company. Indeed, physicians have provided me with a variety of data andinformation following very successful screenings this past weekend on theAthletes for Life Mobile Health Center in Temecula, California. With thiskind of data garnered from real patients in the field, the foundation for theexpansion of our life-saving devices becomes stronger every day."
The Company did not state the exact amount of business contemplated bythese developments, and it cautioned that there is no certainty that any ofthe transactions will close as contemplated -- or at all.
Signalife, Inc. is a life sciences company focused on the monitoring,detection and prevention of disease through continuous biomedical signalmonitoring. Signalife uses its patented signal technology to design anddevelop medical devices, therapies and/or technologies that simplify andreduce the costs of cardiovascular disease.
Signalife is publicly traded on the American Stock Exchange under thesymbol SGN. The website for the company is http://www.Signalife.com. ClearData. Trusted Results.
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are "forward-looking" statements. Forward-looking statements involve known and unknownrisks, which may cause Signalife's actual results in the future to differmaterially from expected results. Factors which could cause or contribute tosuch differences include, but are not limited to, failure to complete thedevelopment and introduction of heart monitoring and other biomedical devicesincorporating Signalife's technology, failure to obtain federal or stateregulatory approvals governing heart monitoring and other biomedical devicesincorporating Signalife's technology, inability to obtain physician, patientor insurance acceptance of for heart monitoring and other biomedicalincorporating Signalife's technology, and the unavailability of financing tocomplete management's plans and objectives, including the development of heartmonitoring and other biomedical incorporating Signalife's technology. Theserisks are qualified in their entirety by cautionary language and risk factorsset forth and to be further described in Signalife's filings with theSecurities and Exchange Commission.
SOURCE Signalife, Inc.
You May Also Like